Literature DB >> 19154919

Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer.

Michael Lanuti1, Amita Sharma, Subba R Digumarthy, Cameron D Wright, Dean M Donahue, John C Wain, Douglas J Mathisen, Jo-Anne O Shepard.   

Abstract

OBJECTIVE: This study evaluated long-term results of radiofrequency ablation for medically inoperable early-stage lung cancer.
METHODS: Thirty-one consecutive patients with biopsy-proven non-small cell lung cancer underwent 38 treatments of computed tomographically guided radiofrequency ablation in a 4.5-year period. All patients were carefully selected and deemed medically ineligible for resection by a multidisciplinary team. Radiofrequency ablation was performed with curative intent with a single or cluster cool-tip electrode. Patients were hospitalized for 23-hour observation.
RESULTS: Treatment was complete in all cases, with no 30-day mortality. Local recurrence was confirmed radiographically by computed tomography, positron emission tomography, or both after 31.5% of treatments (12/38). Two patients were successfully retreated for technical failures related to pneumothorax; 3 underwent radiotherapy with stable disease. Mean maximal diameter of 38 tumors treated was 2.0 +/- 1.0 cm (range 0.8-4.4 cm). After median follow-up of 17 +/- 11 months, 74% of patients (23/31) were alive. Three patients died of metastatic disease; 5 died of pneumonia remote from treatment. The 2- and 4-year survivals were 78% and 47%, respectively. Median overall survival was 30 months. Pneumothorax (13%), pneumonia (16%), and pleural effusion (21%), were the most common complications.
CONCLUSIONS: Radiofrequency ablation of medically inoperable early-stage lung cancer in carefully selected patients yields encouraging midterm results without significant loss of pulmonary function. Local tumor progression appears related to lung tumors larger than 3 cm. Computed tomography and positron emission tomography need further validation for the early identification of local tumor progression following radiofrequency ablation.

Entities:  

Mesh:

Year:  2008        PMID: 19154919     DOI: 10.1016/j.jtcvs.2008.08.034

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  50 in total

Review 1.  Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances.

Authors:  S L Smith; P E Jennings
Journal:  Br J Radiol       Date:  2014-12-03       Impact factor: 3.039

Review 2.  Expert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 edition.

Authors:  Bao-Dong Liu; Xiu-Yi Zhi
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

Review 3.  Expert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 edition.

Authors:  Bao-Dong Liu; Xiu-Yi Zhi
Journal:  Ann Transl Med       Date:  2015-06

Review 4.  Expert consensus on image-guided radiofrequency ablation of pulmonary tumors-2015 edition.

Authors:  Bao-Dong Liu; Xiu-Yi Zhi
Journal:  Transl Lung Cancer Res       Date:  2015-06

Review 5.  Alternative to surgery in early stage NSCLC-interventional radiologic approaches.

Authors:  Kyungmouk Steve Lee; Bradley B Pua
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 6.  Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?

Authors:  Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Gilbert Massard
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-10

7.  Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what?

Authors:  Rameses Sroufe; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.

Authors:  T Schneider; A Sevko; C P Heussel; L Umansky; P Beckhove; H Dienemann; S Safi; J Utikal; H Hoffmann; V Umansky
Journal:  Clin Exp Immunol       Date:  2015-04-15       Impact factor: 4.330

9.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.

Authors:  Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

10.  Non-surgical management of stage I lung cancer.

Authors:  Elizabeth M Gore
Journal:  F1000 Med Rep       Date:  2010-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.